Nivolumab in Combination With Chemoradiotherapy for Intermediate- and High-Risk Locally Advanced HNSCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504
Int. J. Radiat. Oncol. Biol. Phys 2022 Oct 10;[EPub Ahead of Print], ML Gillison, RL Ferris, J Harris, AD Colevas, LK Mell, C Kong, RC Jordan, KL Moore, MT Truong, C Kirsch, A Chakravarti, DM Blakaj, DA Clump, JP Ohr, JF Deeken, MF Gensheimer, NF Saba, JA Dorth, DI Rosenthal, RS Leidner, RJ Kimple, M Machtay, WJ Curran, P Torres-Saavedra, QT LeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.